title: Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice.
abstract: Respiratory syncytial virus (RSV) is a high priority target for vaccine development. One concern in RSV vaccine development is that a non-live virus vaccine would predispose for enhanced disease similar to that seen with the formalin inactivated RSV (FI-RSV) vaccine. Since a mAb specific to RSV G protein can reduce pulmonary inflammation and eosinophilia seen after RSV infection of FI-RSV vaccinated mice, we hypothesized that RSV G peptides that induce antibodies with similar reactivity may limit enhanced disease after subunit or other non-live RSV vaccines. In support of this hypothesis, we show that FI-RSV vaccinated mice administered RSV G peptide vaccines had a significant reduction in enhanced disease after RSV challenge. These data support the importance of RSV G during infection to RSV disease pathogenesis and suggest that use of appropriately designed G peptide vaccines to reduce the risk of enhanced disease with non-live RSV vaccines merits further study.
authors.affiliation: National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.
authors.forename: Gertrud U
authors.initials: GU
authors.lastname: Rey
authors.affiliation: National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.
authors.forename: Congrong
authors.initials: C
authors.lastname: Miao
authors.affiliation: National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.
authors.forename: Hayat
authors.initials: H
authors.lastname: Caidi
authors.affiliation: National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.
authors.forename: Suvang U
authors.initials: SU
authors.lastname: Trivedi
authors.affiliation: National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.
authors.forename: Jennifer L
authors.initials: JL
authors.lastname: Harcourt
authors.affiliation: College of Veterinary Medicine, Department of Infectious Disease, University of Georgia, Athens, Georgia, United States of America.
authors.forename: Ralph A
authors.initials: RA
authors.lastname: Tripp
authors.affiliation: Emory University Department of Pediatrics and Children's Healthcare of Atlanta, Emory Children's Center, Atlanta, Georgia, United States of America.
authors.forename: Larry J
authors.initials: LJ
authors.lastname: Anderson
authors.affiliation: National Center for Immunization and Respiratory Diseases, Division of Viral Diseases, Gastroenteritis and Respiratory Viruses Laboratory Branch, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, United States of America.
authors.forename: Lia M
authors.initials: LM
authors.lastname: Haynes
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood*; D005557:Formaldehyde; D007114:Immunization; D008168:Lung / Q000187:drug effects / Q000276:immunology / Q000821:virology; D051379:Mice; D008807:Mice, Inbred BALB C; D008969:Molecular Sequence Data; D010455:Peptides / Q000008:administration & dosage / Q000737:chemistry / Q000276:immunology*; D018357:Respiratory Syncytial Virus Infections / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D022261:Respiratory Syncytial Virus Vaccines / Q000008:administration & dosage / Q000276:immunology*; D012136:Respiratory Syncytial Viruses / Q000737:chemistry / Q000276:immunology*; D015164:Vaccines, Inactivated; D014760:Viral Fusion Proteins / Q000737:chemistry / Q000276:immunology*
chemical_list: D000914:Antibodies, Viral; C502275:G glycoprotein, Respiratory syncytial virus; D010455:Peptides; D022261:Respiratory Syncytial Virus Vaccines; D015164:Vaccines, Inactivated; D014760:Viral Fusion Proteins; D005557:Formaldehyde